论文部分内容阅读
随着免疫学的发展，脑胶质瘤的免疫治疗也得到了很快地发展，尤以重组人类白细胞介素2（rIL－2）及淋巴因子活化的杀伤细胞（IAK）在脑胶质瘤的免疫治疗作用特别引人注目。一、rIL-2及IAK的概况及生物学活性IL－2是MOIggn等[1]于1976年发现的一种T细胞增殖因子，是一种由133个
With the development of immunology, the immunotherapy of gliomas has also been rapidly developed. In particular, recombinant human interleukin 2 (rIL-2) and lymphokine-activated killer cells (IAK) are present in gliomas. The immunotherapy effect is particularly noticeable. I. Overview and Biological Activity of rIL-2 and IAK IL-2 is a T cell proliferation factor discovered by MOIggn et al. [1] in 1976 and is a type of 133 cells.